StreetInsider.com News Articles

Candel publishes phase 3 prostate cancer trial data in Lancet Oncology

Tue, 02 Jun 2026 08:05:16 -0400

Candel Therapeutics Inc. (NASDAQ: CADL) announced the publication of results from its pivotal phase 3 clinical trial of aglatimagene besadenovec in The Lancet Oncology, according to a company statement.

The randomized, double-blind, placebo-controlled trial enrolled 745 patients with intermediate- to high-risk localized prostate cancer. The study evaluated aglatimagene plus valacyclovir in combination with standard radiotherapy administered with curative intent.

The trial met its primary endpoint, showing a 30% improvement in disease-free survival in the aglatimagene arm compared to placebo (hazard ratio 0.70; 95% confidence interval 0.52-0.94; p=0.016). The treatment also demonstrated a 38% improvement in prostate cancer-specific disease-free survival (hazard ratio 0.62;

Candel Therapeutics Announces Publication in The Lancet Oncology of Pivotal Phase 3 Data Demonstrating Significant Improvement in Disease-Free Survival with Aglatimagene Besadenovec (CAN-2409) in Loca

Tue, 02 Jun 2026 08:05:00 -0400

Peer reviewed publication details pivotal data, demonstrating 30% improvement in disease-free survival (DFS) in patients with localized prostate cancer undergoing standard-of-care radiotherapy with curative intent combined with aglatimagene besadenovec (aglatimagene) plus valacyclovir compared to placebo plus valacyclovir
Findings support that addition of aglatimagene to standard-of-care radiotherapy can provide a meaningful benefit without increasing clinically significant toxicity
Data reported in this publication will support planned Biologics License Application (BLA) submission for aglatimagene in fourth quarter of 2026

NEEDHAM, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel

Candel Therapeutics Announces Publication in The Lancet Oncology of Pivotal Phase 3 Data Demonstrating Significant Improvement in Disease-Free Survival with Aglatimagene Besadenovec (CAN-2409) in Loca

Tue, 02 Jun 2026 08:05:00 -0400

Peer reviewed publication details pivotal data, demonstrating 30% improvement in disease-free survival (DFS) in patients with localized prostate cancer undergoing standard-of-care radiotherapy with curative intent combined with aglatimagene besadenovec (aglatimagene) plus valacyclovir compared to placebo plus valacyclovir
Findings support that addition of aglatimagene to standard-of-care radiotherapy can provide a meaningful benefit without increasing clinically significant toxicity
Data reported in this publication will support planned Biologics License Application (BLA) submission for aglatimagene in fourth quarter of 2026

NEEDHAM, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mon, 01 Jun 2026 16:05:00 -0400

NEEDHAM, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that on May 31, 2026, the Compensation Committee of Candel’s Board of Directors (the Board) granted to three new employees, stock options to purchase an aggregate of 63,000 shares of the Company’s common stock, with a per share exercise price of $8.30.

The inducement stock options were made under the Company’s 2025 Inducement Plan (the Plan) and will vest

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mon, 01 Jun 2026 16:05:00 -0400

The inducement stock options were made under the Company’s 2025 Inducement Plan (the Plan) and will vest

Candel Therapeutics Inc. (CADL) PT Raised to $9 at BofA Securities

Mon, 18 May 2026 15:22:59 -0400

BofA Securities analyst Alec Stranahan raised the price target on Candel Therapeutics Inc. (NASDAQ: CADL) to $9.00 (from $7.00) while maintaining a Neutral rating.

The analyst comments "Candel’s update for aglatimagene (CAN-2409) in localized intermediate- to high-risk prostate cancer is incrementally positive in our view, with extended follow-up directionally suggesting treatment benefit continues to accrue over time. The company reported 39% improvement in prostate cancer specific disease-free survival (DFS) with favorable trends in key biologic secondary endpoints (more below). We think the data supports the thesis that improved local tumor control and higher 2-year pathologic complete response could translate to meaningful

Candel Therapeutics Inc. (CADL) PT Raised to $9 at BofA Securities

Mon, 18 May 2026 15:22:59 -0400

BofA Securities analyst Alec Stranahan raised the price target on Candel Therapeutics Inc. (NASDAQ: CADL) to $9.00 (from $7.00) while maintaining a Neutral rating.

Form 8-K Candel Therapeutics, For: May 15

Fri, 15 May 2026 16:18:00 -0400

si-local-file:///var/storage/secattach/20260515/26505666.html

Form 8-K Candel Therapeutics, For: May 15

Fri, 15 May 2026 16:18:00 -0400

si-local-file:///var/storage/secattach/20260515/26505666.html

Candel Therapeutics reports extended clinical benefits in phase 3 prostate cancer trial

Fri, 15 May 2026 16:05:16 -0400

Candel Therapeutics, Inc. (NASDAQ: CADL) announced extended follow-up data from its phase 3 trial of aglatimagene besadenovec in localized prostate cancer, showing a 39% improvement in prostate cancer-specific disease-free survival compared to placebo after a median follow-up of 58 months.

The randomized, double-blind, placebo-controlled trial enrolled 745 patients with intermediate- to high-risk localized prostate cancer. Results showed a hazard ratio of 0.61 with a 95% confidence interval of 0.44 to 0.85 and a p-value of 0.0031 for the primary endpoint.

The data were presented at the American Urological Association 2026 Annual Meeting in Washington, D.C. The follow-up represents an additional 20 months

Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints in Patients from Phase 3 Trial of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer Under Prolonge

Fri, 15 May 2026 16:05:00 -0400

Extended follow-up data from the phase 3 study (20 months after reported topline data, median follow-up 58 months) confirmed a statistically significant and clinically meaningful improvement in prostate cancer–specific disease-free survival (DFS) of 39% after aglatimagene administration compared to placebo, reinforcing the potential of aglatimagene to reduce the risk of tumor recurrence in men receiving radiotherapy for localized disease.
Clinical benefit demonstrated in the intention-to treat (ITT) population by secondary and clinically relevant exploratory endpoints with numerical improvements observed in time to biochemical failure (TTBF), lower incidence of and increased time to metastases, and

Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints in Patients from Phase 3 Trial of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer Under Prolonge

Fri, 15 May 2026 16:05:00 -0400

Extended follow-up data from the phase 3 study (20 months after reported topline data, median follow-up 58 months) confirmed a statistically significant and clinically meaningful improvement in prostate cancer–specific disease-free survival (DFS) of 39% after aglatimagene administration compared to placebo, reinforcing the potential of aglatimagene to reduce the risk of tumor recurrence in men receiving radiotherapy for localized disease.
Clinical benefit demonstrated in the intention-to treat (ITT) population by secondary and clinically relevant exploratory endpoints with numerical improvements observed in time to biochemical failure (TTBF), lower incidence of and increased time to metastases, and

Form SCHEDULE 13G Candel Therapeutics, Filed by: RTW INVESTMENTS, LP

Fri, 15 May 2026 08:09:00 -0400
si-local-file:///var/storage/secattach/20260515/26499877.html

Form SCHEDULE 13G Candel Therapeutics, Filed by: RTW INVESTMENTS, LP

Fri, 15 May 2026 08:09:00 -0400
si-local-file:///var/storage/secattach/20260515/26499877.html

Form 10-Q Candel Therapeutics, For: Mar 31

Thu, 14 May 2026 08:31:00 -0400
si-local-file:///var/storage/secattach/20260514/26490660.html

Form 10-Q Candel Therapeutics, For: Mar 31

Thu, 14 May 2026 08:31:00 -0400
si-local-file:///var/storage/secattach/20260514/26490660.html

Candel Therapeutics, Inc. (CADL) Tops Q1 EPS by 20c

Thu, 14 May 2026 08:28:06 -0400

Candel Therapeutics, Inc. (NASDAQ: CADL) reported Q1 EPS of ($0.14), $0.20 better than the analyst estimate of ($0.34).
For earnings history and earnings-related data on Candel Therapeutics, Inc. (CADL) click here.

Form 8-K Candel Therapeutics, For: May 14

Thu, 14 May 2026 08:15:00 -0400
si-local-file:///var/storage/secattach/20260514/26490515.html

Form 8-K Candel Therapeutics, For: May 14

Thu, 14 May 2026 08:15:00 -0400
si-local-file:///var/storage/secattach/20260514/26490515.html

Candel Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

Thu, 14 May 2026 08:05:00 -0400

Company plans to submit a Biologics License Application (BLA) for aglatimagene besadenovec (aglatimagene or CAN-2409) in localized, intermediate- to high-risk prostate cancer in Q4 2026
Announced purpose-built commercial partnership with EVERSANA® to support potential U.S. launch of aglatimagene in localized prostate cancer
Company reported extended survival tail observed in trial of aglatimagene in advanced non-small cell lung cancer (NSCLC) patients with inadequate response to immune checkpoint inhibitors (ICI)
Company to report extended follow-up data from the positive phase 3 clinical trial of aglatimagene in patients with localized, intermediate- to high-risk prostate cancer at the American Urological Association (AUA) 2026

Candel Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

Thu, 14 May 2026 08:05:00 -0400

Company plans to submit a Biologics License Application (BLA) for aglatimagene besadenovec (aglatimagene or CAN-2409) in localized, intermediate- to high-risk prostate cancer in Q4 2026
Announced purpose-built commercial partnership with EVERSANA® to support potential U.S. launch of aglatimagene in localized prostate cancer
Company reported extended survival tail observed in trial of aglatimagene in advanced non-small cell lung cancer (NSCLC) patients with inadequate response to immune checkpoint inhibitors (ICI)
Company to report extended follow-up data from the positive phase 3 clinical trial of aglatimagene in patients with localized, intermediate- to high-risk prostate cancer at the American Urological Association (AUA) 2026

Candel Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

Thu, 14 May 2026 08:05:00 -0400

Company plans to submit a Biologics License Application (BLA) for aglatimagene besadenovec (aglatimagene or CAN-2409) in localized, intermediate- to high-risk prostate cancer in Q4 2026
Announced purpose-built commercial partnership with EVERSANA® to support potential U.S. launch of aglatimagene in localized prostate cancer
Company reported extended survival tail observed in trial of aglatimagene in advanced non-small cell lung cancer (NSCLC) patients with inadequate response to immune checkpoint inhibitors (ICI)
Company to report extended follow-up data from the positive phase 3 clinical trial of aglatimagene in patients with localized, intermediate- to high-risk prostate cancer at the American Urological Association (AUA) 2026

Candel Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

Thu, 14 May 2026 08:05:00 -0400

Company plans to submit a Biologics License Application (BLA) for aglatimagene besadenovec (aglatimagene or CAN-2409) in localized, intermediate- to high-risk prostate cancer in Q4 2026
Announced purpose-built commercial partnership with EVERSANA® to support potential U.S. launch of aglatimagene in localized prostate cancer
Company reported extended survival tail observed in trial of aglatimagene in advanced non-small cell lung cancer (NSCLC) patients with inadequate response to immune checkpoint inhibitors (ICI)
Company to report extended follow-up data from the positive phase 3 clinical trial of aglatimagene in patients with localized, intermediate- to high-risk prostate cancer at the American Urological Association (AUA) 2026

Candel Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

Thu, 14 May 2026 08:05:00 -0400

Company plans to submit a Biologics License Application (BLA) for aglatimagene besadenovec (aglatimagene or CAN-2409) in localized, intermediate- to high-risk prostate cancer in Q4 2026
Announced purpose-built commercial partnership with EVERSANA® to support potential U.S. launch of aglatimagene in localized prostate cancer
Company reported extended survival tail observed in trial of aglatimagene in advanced non-small cell lung cancer (NSCLC) patients with inadequate response to immune checkpoint inhibitors (ICI)
Company to report extended follow-up data from the positive phase 3 clinical trial of aglatimagene in patients with localized, intermediate- to high-risk prostate cancer at the American Urological Association (AUA) 2026

Candel Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

Thu, 14 May 2026 08:05:00 -0400

Company plans to submit a Biologics License Application (BLA) for aglatimagene besadenovec (aglatimagene or CAN-2409) in localized, intermediate- to high-risk prostate cancer in Q4 2026
Announced purpose-built commercial partnership with EVERSANA® to support potential U.S. launch of aglatimagene in localized prostate cancer
Company reported extended survival tail observed in trial of aglatimagene in advanced non-small cell lung cancer (NSCLC) patients with inadequate response to immune checkpoint inhibitors (ICI)
Company to report extended follow-up data from the positive phase 3 clinical trial of aglatimagene in patients with localized, intermediate- to high-risk prostate cancer at the American Urological Association (AUA) 2026